Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Christov

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|August 31, 2000
Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesisA Shilkaitis, J Graves, R R Mehta, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1994
Cell proliferation in hyperplastic and in situ carcinoma lesions of the breast estimated by in vivo labeling with bromodeoxyuridineK Christov, K L Chew, B M Ljung, et al.
Science (New York, N.Y.)|September 11, 1999
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapyP G Komarov, E A Komarova, R V Kondratov, et al.
The American Journal of Pathology|June 1, 1991
Proliferation of normal breast epithelial cells as shown by in vivo labeling with bromodeoxyuridineK Christov, K L Chew, B M Ljung, et al.
Cancer Research|August 14, 1999
A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agentsB D Chang, E V Broude, M Dokmanovic, et al.
British Journal of Cancer|June 6, 2013
p28, a first in class peptide inhibitor of cop1 binding to p53T Yamada, K Christov, A Shilkaitis, et al.
Plants (Basel, Switzerland)|September 9, 2022
Reactivation of the Photosynthetic Apparatus of Resurrection Plant <i>Haberlea rhodopensis</i> during the Early Phase of Recovery from Drought- and Freezing-Induced DesiccationGergana Mihailova, Nikolai K Christov, Éva Sárvári, et al.
British Journal of Cancer|March 2, 2013
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumoursM A Warso, J M Richards, D Mehta, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|August 31, 2000
Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesisA Shilkaitis, J Graves, R R Mehta, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1994
Cell proliferation in hyperplastic and in situ carcinoma lesions of the breast estimated by in vivo labeling with bromodeoxyuridineK Christov, K L Chew, B M Ljung, et al.
Science (New York, N.Y.)|September 11, 1999
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapyP G Komarov, E A Komarova, R V Kondratov, et al.
The American Journal of Pathology|June 1, 1991
Proliferation of normal breast epithelial cells as shown by in vivo labeling with bromodeoxyuridineK Christov, K L Chew, B M Ljung, et al.
Cancer Research|August 14, 1999
A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agentsB D Chang, E V Broude, M Dokmanovic, et al.
British Journal of Cancer|June 6, 2013
p28, a first in class peptide inhibitor of cop1 binding to p53T Yamada, K Christov, A Shilkaitis, et al.
Plants (Basel, Switzerland)|September 9, 2022
Reactivation of the Photosynthetic Apparatus of Resurrection Plant <i>Haberlea rhodopensis</i> during the Early Phase of Recovery from Drought- and Freezing-Induced DesiccationGergana Mihailova, Nikolai K Christov, Éva Sárvári, et al.
British Journal of Cancer|March 2, 2013
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumoursM A Warso, J M Richards, D Mehta, et al.
Pageof 5